$SNSS a little reminder “The value of this program and other non-covalent BTK inhibitors was recently demonstrated by the $2.7bn offer to buyout ArQule from Merck. ArQule presented the final results from its Phase I dosing study of ARQ 531 at the same ASH meeting, which (consistent with previous results) showed a strong response and 8/9 patients with a C481S mutation achieved a PR. The fact that Merck made such a high value offer at such an early stage also highlights the importance of these dosing studies, because we can have reasonable confidence that these early signs of efficacy can translate to later studies on account of the mechanism already being vetted. This is also the case for Sunesis, and we expect a major value inflection if the company can similarly prove that vecabrutinib can generate meaningful clinical responses.
  • 3
  • 1